Coultreon Biopharma, formerly Onco3R Therapeutics (now rebranded), raised a $125 million Series A led by Sofinnova Investments to advance COL-5671, an oral small-molecule inhibitor of salt-inducible kinase 3 (SIK3). The company plans to move the Phase I program toward Phase II with initial autoimmune focus areas including psoriasis and ulcerative colitis. Pierre Raboisson, Coultreon’s CEO, framed COL-5671’s differentiation around dual immunomodulatory effects: lowering pro-inflammatory cytokines such as TNFα and IL-23 while boosting the anti-inflammatory cytokine IL-10. The oral, once-daily approach is positioned to compete with injectable biologics by offering broader and potentially more durable disease control. Investors backing the round included co-leads Forbion and Novo Holdings, alongside Galapagos, Regeneron Ventures, and others. The syndicate structure underscores continued appetite for translational immunology targets that can generate clear clinical proof-of-concept on a defined timeline.